Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
Grünenthal and NovaQuest announced today that they have entered into an agreement to advance the global clinical Phase III programme of Grünenthal's...
Grünenthal, an international science-driven pharmaceutical company, announced that it has donated 400.000€ to the Red Cross to support humanitarian...
The European Pain Federation EFIC® and the pharmaceutical company Grünenthal have announced the five recipients of the EFIC-Grünenthal Grant (E-G-G). ...
Today, Grünenthal announced that the first participants have been enrolled in a randomised, placebo- and active-controlled clinical trial for its...
Grünenthal announced today that its U.S. subsidiary, Averitas Pharma Inc., enrolled the first patient in the randomised, double-blind trial AV001....
Grünenthal announced today that the first volunteers have been enrolled in a Phase I trial of its Glucocorticoid Receptor Modulator (GRM). The oral...
Grünenthal is deeply saddened by the situation of the people affected by the flood disaster in Germany. Staff and executive management have set up a...
Grünenthal, an international pharmaceutical company headquartered in Aachen, announced today that it will be recognised as one of the best employers...
Today, Grünenthal has announced the acquisition of Mestex AG through the takeover of all of its shares and options. Mestex AG is a Swiss biotech...
Grünenthal Germany is now certified as a Great Place to Work® and a Great Start! company for apprentices. The company was awarded these two...
Grünenthal has announced the successful extension of its existing €535 million term loan bank facilities. This amendment was conducted in the broader ...
Grünenthal today announced the successful completion of its acquisition of the European rights to CRESTOR™ (excluding Spain and the UK) for a total...
Florian Dieckmann joined Grünenthal as the new Vice President and Head Global Communications on 1 January 2021. He succeeds Štěpán Kráčala, who...
Grünenthal announced today that the first participants have been enrolled in a Phase I trial of a peripherally restricted Nociceptin/orphanin peptide ...
Grünenthal, a global science-based, privately-owned pharmaceutical company, today announced that it has agreed to acquire the European rights...
Grünenthal announced today that its U.S. subsidiary Averitas Pharma, Inc. received U.S. Food and Drug Administration (FDA) approval for QUTENZA®...
Grünenthal, a global leader in pain management and related diseases, has announced it will now include electric and hybrid engines in the fleet of...
Grünenthal announced today that it has officially inaugurated its Innovation Hub in Boston, Massachusetts to strengthen and expand its network with...
Averitas Pharma, Inc., a subsidiary of GRT US Holding, Inc. and member of the Grünenthal Group, announced today that the supplemental New Drug...
Grünenthal announced today that Jan Adams, MD has been appointed Chief Scientific Officer (CSO) and Member of the Corporate Executive Board effective ...
The European Pain Federation EFIC® and the pharmaceutical company Grünenthal have announced the five research projects that will receive funding as...
Grünenthal announced today that Fabian Raschke has been appointed Chief Financial Officer (CFO) and Member of the Corporate Executive Board. He will...
Grünenthal and OnDosis announced today that they have entered into an exclusive collaboration to develop the OnDosis' technology for prescription...
Grünenthal announced today that it has acquired the US-based pharmaceutical company Averitas Pharma, thereby extending its commercial footprint to...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.